Blood Test Distinguishes Neuroendocrine Subtype of Advanced Prostate Cancer
Researchers have developed a blood test that can reliably detect NEPC and differentiate it from CRPC-adenocarcinoma.
Read MorePosted by Andy Lundin | Jan 10, 2024 | Prostate |
Researchers have developed a blood test that can reliably detect NEPC and differentiate it from CRPC-adenocarcinoma.
Read MorePosted by Andy Lundin | Jan 3, 2024 | Prostate |
ArteraAI says the CMS decided on the payment rate for the ArteraAI Prostate Test, a clinical diagnostic laboratory test for prostate cancer.
Read MorePosted by Chris Wolski | Dec 26, 2023 | Prostate |
UCLA Researchers have received a five-year, $3 million grant to develop AI that can detect and predict aggressive prostate cancer.
Read MorePosted by Andy Lundin | Nov 6, 2023 | Prostate |
Black men are more likely to develop prostate cancer than white men and more likely to have advanced disease and to die than white men.
Read MorePosted by Andy Lundin | Oct 16, 2023 | Prostate |
ArteraAI will present data demonstrating the successful validation of its prognostic model in advanced prostate cancer.
Read More